DK1240186T3 - Forbedringer i eller relateret til immunrespons mod HIV - Google Patents

Forbedringer i eller relateret til immunrespons mod HIV

Info

Publication number
DK1240186T3
DK1240186T3 DK00985690.7T DK00985690T DK1240186T3 DK 1240186 T3 DK1240186 T3 DK 1240186T3 DK 00985690 T DK00985690 T DK 00985690T DK 1240186 T3 DK1240186 T3 DK 1240186T3
Authority
DK
Denmark
Prior art keywords
hiv
immune response
immunogen
synthetic polypeptide
protein
Prior art date
Application number
DK00985690.7T
Other languages
English (en)
Inventor
Tomas Hanke
Andrew James Mcmichael
Original Assignee
Medical Res Council
Int Aids Vaccine Initiative
Univ Nairobi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9930294.5A external-priority patent/GB9930294D0/en
Priority claimed from GB0025234A external-priority patent/GB0025234D0/en
Application filed by Medical Res Council, Int Aids Vaccine Initiative, Univ Nairobi filed Critical Medical Res Council
Application granted granted Critical
Publication of DK1240186T3 publication Critical patent/DK1240186T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK00985690.7T 1999-12-23 2000-12-22 Forbedringer i eller relateret til immunrespons mod HIV DK1240186T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9930294.5A GB9930294D0 (en) 1999-12-23 1999-12-23 Improvements in or relating to immune responses to HIV
GB0025234A GB0025234D0 (en) 2000-10-14 2000-10-14 Improvements in or relating to immune responses to HIV
PCT/GB2000/004984 WO2001047955A2 (en) 1999-12-23 2000-12-22 Improvements in or relating to immune responses to hiv

Publications (1)

Publication Number Publication Date
DK1240186T3 true DK1240186T3 (da) 2010-05-31

Family

ID=26245157

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00985690.7T DK1240186T3 (da) 1999-12-23 2000-12-22 Forbedringer i eller relateret til immunrespons mod HIV

Country Status (15)

Country Link
US (1) US7993651B2 (da)
EP (1) EP1240186B1 (da)
JP (1) JP4805511B2 (da)
CN (1) CN1213068C (da)
AT (1) ATE457996T1 (da)
AU (1) AU784679B2 (da)
BR (1) BR0016510A (da)
CA (1) CA2392877C (da)
CY (1) CY1110917T1 (da)
DE (1) DE60043856D1 (da)
DK (1) DK1240186T3 (da)
ES (1) ES2341429T3 (da)
MX (1) MXPA02006379A (da)
PT (1) PT1240186E (da)
WO (1) WO2001047955A2 (da)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1980617A1 (en) 1998-12-31 2008-10-15 Novartis Vaccines and Diagnostics, Inc. Improved expression of HIV polypeptides and production of virus-like particles
WO2000039304A2 (en) 1998-12-31 2000-07-06 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
WO2001092470A2 (en) 2000-03-02 2001-12-06 Emory University Dna expression vectors and methods of use
US8623379B2 (en) 2000-03-02 2014-01-07 Emory University Compositions and methods for generating an immune response
PT1372710E (pt) 2001-03-08 2009-12-21 Us Gov Health & Human Serv Vam modificado que expressa os genes gag e pol do envelope de vih
CA2452015C (en) 2001-07-05 2012-07-03 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
MXPA04002631A (es) * 2001-09-20 2004-07-08 Glaxo Group Ltd Vacunas de adn optimizadas por codon gag-vih.
GB0225788D0 (en) 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
US7425611B2 (en) * 2003-03-28 2008-09-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Immunogenic HIV-1 multi-clade, multivalent constructs and methods of their use
AU2004279362B2 (en) 2003-09-15 2011-03-17 Genvec, Inc. HIV vaccines based on ENV of multiple clades of HIV
WO2005030964A1 (en) * 2003-09-24 2005-04-07 Oxxon Therapeutics Limited Hiv pharmaccines
WO2005047483A2 (en) 2003-11-12 2005-05-26 Medical Research Council Renta: an hiv immunogen and uses thereof
TW200613554A (en) * 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
ATE527281T1 (de) 2004-07-16 2011-10-15 Us Gov Health & Human Serv Impfstoffe gegen aids umfassend cmv/r nucleinsäurekonstrukte
GB0417494D0 (en) * 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
CA2597511A1 (en) * 2005-02-24 2006-11-23 Medical Research Council Hivcon: an hiv immunogen and uses thereof
DK2029168T3 (da) 2006-06-02 2013-01-14 Int Aids Vaccine Initiative HIV-1 Clade A konsensussekvenser, antigener og transgener.
WO2010096561A1 (en) * 2009-02-18 2010-08-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synthetic hiv/siv gag proteins and uses thereof
KR20120093941A (ko) * 2009-10-08 2012-08-23 버베리안 노딕 에이/에스 인간에서 ｈｉｖ에 대한 광범위한 ｔ-세포 반응의 생성
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
CA2817418A1 (en) * 2010-11-10 2012-05-18 Laboratorios Del Dr. Esteve, S.A. Highly immunogenic hiv p24 sequences
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
US9347065B2 (en) 2012-03-29 2016-05-24 International Aids Vaccine Initiative Methods to improve vector expression and genetic stability
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
ES2807173T3 (es) 2012-09-10 2021-02-22 Int Aids Vaccine Initiative Inmunógenos de anticuerpos ampliamente neutralizantes del VIH-1, métodos de generación y usos de los mismos
EP2745845A1 (en) 2012-12-19 2014-06-25 Centre Hospitalier Universitaire de Bordeaux A method for preventing or treating an HIV infection
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3116895A4 (en) * 2014-03-12 2017-08-16 Temple University Of The Commonwealth System Of Higher Education Dr6 receptor mediates the leukemia differentiation activity of angiocidin: a potent anti-tumor peptide
US10093720B2 (en) 2014-06-11 2018-10-09 International Aids Vaccine Initiative Broadly neutralizing antibody and uses thereof
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US9925258B2 (en) 2015-10-02 2018-03-27 International Aids Vaccine Initiative Replication-competent VSV-HIV Env vaccines
EP3426353A4 (en) 2016-03-09 2020-05-06 The University of Massachusetts USE OF MODIFIED HIV-1 TO GENERATE FULLY HUMAN ANTIBODIES
KR20220011685A (ko) 2019-05-22 2022-01-28 길리애드 사이언시즈, 인코포레이티드 Tlr7 조절 화합물과 hiv 백신의 조합
AU2020298552A1 (en) * 2019-07-02 2022-03-03 Seattle Project Corp. HIV antigens and MHC complexes
EP4058058A1 (en) 2019-11-14 2022-09-21 Aelix Therapeutics S.L. Dosage regimens for vaccines
WO2021185851A1 (en) 2020-03-17 2021-09-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Vaccine compositions for hiv prevention and treatment
CA3173793A1 (en) 2020-04-03 2021-10-07 Andrew Ferguson Infectious disease antigens and vaccines
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2869063B2 (ja) 1985-04-08 1999-03-10 ジエネテイツク システムズ コ−ポレイシヨン ＬＡＶに対する抗体と免疫的に反応性であるｇａｇによりコードされたペプチドの発現及び使用
US4784941A (en) 1985-04-08 1988-11-15 Genetic Systems Corporation Expression and diagnostic use of pENV-3 encoded peptides which are immunologically reactive with antibodies to LAV
US4629783A (en) 1985-04-29 1986-12-16 Genetic Systems Corporation Synthetic antigen for the detection of AIDS-related disease
US5175098A (en) 1985-08-07 1992-12-29 Genetic Systems Corporation Expression and diagnostic use of gag encoded peptides which are immunologically reactive with antibodies to HIV
US5175097A (en) 1985-08-07 1992-12-29 Genetic Systems Corporation Expression and diagnostic use of GAG-1 encoded peptides which are immunologically reactive with antibodies to HIV
US5134227A (en) 1986-02-27 1992-07-28 Centocor, Inc. DNA encoding immunoreactive, chimeric HTLV-III GAG proteins
US4808536A (en) 1986-02-27 1989-02-28 Centocor, Inc. Immunochemical method for detection of antibody against HTLV-III core protein based upon recombinant HTLV-III gag gene encoded protein
US4822606A (en) 1986-04-07 1989-04-18 Duke University Immunosuppressive synthetic peptides and analogs thereof based on retroviral envelope sequences
US5993819A (en) 1987-09-08 1999-11-30 Duke University Synthetic vaccine for protection against human immunodeficiency virus infection
GB2220939B (en) 1988-06-10 1992-02-26 Medical Res Council Peptide fragments of hiv and their use in vaccines and diagnosis
US5817318A (en) 1989-05-03 1998-10-06 Connaught Laboratories Limited Synthetic peptides for an HIV-1 vaccine
US5210181A (en) 1989-05-15 1993-05-11 Akzo N.V. T-lymphotropic retrovirus peptide
GB8918200D0 (en) 1989-08-09 1989-09-20 Medical Res Council The peptide fragments of hiv
CA2025634A1 (en) 1989-09-19 1991-03-20 Thomas Fuerst Peptides including ctl epitopes of hiv proteins and use thereof
DE3934366A1 (de) 1989-10-14 1991-04-18 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum
US5480967A (en) 1990-01-05 1996-01-02 United Biomedical, Inc. HIV-1 core protein fragments
DE69231705T2 (de) * 1992-06-04 2001-10-18 The Research Foundation For Microbial Diseases Of Osaka University, Suita Gag-Env Fusion-Antigen aus HIV
JP3277045B2 (ja) 1992-10-06 2002-04-22 デイド・ベーリング・マルブルク・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング Ｈｉｖ−グループのレトロウイルスおよびその使用
JPH08511007A (ja) 1993-06-09 1996-11-19 コノート ラボラトリーズ リミテッド タンデム合成ｈｉｖ−１ペプチド
US6225045B1 (en) 1996-05-13 2001-05-01 Ribotargets, Ltd. Assays for screening for inhibitors of HIV
AU731367B2 (en) 1996-08-09 2001-03-29 Viral Technologies, Inc. HIV p-17 peptide fragment, compositions containing and methods for producing and using same
US6093400A (en) 1996-08-09 2000-07-25 Cel Sci Corporation Modified HGP-30 peptides, conjugates, compositions and methods of use
US6271354B1 (en) 1997-04-03 2001-08-07 Thomas Jefferson University Chimeric viral proteins
GB9711957D0 (en) * 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
AU6139699A (en) * 1998-09-11 2000-04-03 Children's Medical Center Corporation Packaging cell lines for hiv-derived retroviral vector particles
HK1044040A1 (zh) * 1998-11-16 2002-10-04 德克萨斯州立大学董事会 Hiv-特异的t-细胞诱导
WO2000039304A2 (en) * 1998-12-31 2000-07-06 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
EP1088889A1 (en) 1999-10-01 2001-04-04 University Of Cambridge Recombinant double hybrid filamentous bacteriophage

Also Published As

Publication number Publication date
JP4805511B2 (ja) 2011-11-02
US20030108562A1 (en) 2003-06-12
MXPA02006379A (es) 2004-06-21
US7993651B2 (en) 2011-08-09
CN1434831A (zh) 2003-08-06
CY1110917T1 (el) 2015-06-10
DE60043856D1 (de) 2010-04-01
EP1240186A2 (en) 2002-09-18
BR0016510A (pt) 2002-08-27
PT1240186E (pt) 2010-03-25
WO2001047955A2 (en) 2001-07-05
JP2003518931A (ja) 2003-06-17
AU2208901A (en) 2001-07-09
HK1058048A1 (en) 2004-04-30
ATE457996T1 (de) 2010-03-15
CA2392877C (en) 2011-11-15
WO2001047955A3 (en) 2002-05-10
ES2341429T3 (es) 2010-06-21
EP1240186B1 (en) 2010-02-17
CN1213068C (zh) 2005-08-03
CA2392877A1 (en) 2001-07-05
AU784679B2 (en) 2006-05-25

Similar Documents

Publication Publication Date Title
DE60043856D1 (de) Verbesserungen in oder in bezug auf immunantworten gegen hiv
Haigwood et al. Importance of hypervariable regions of HIV-1 gp120 in the generation of virus neutralizing antibodies
DK1278534T3 (da) Fremgangsmåder og sammensætninger til svækkelse af multiplikationen af HIV-1
EP0339504A3 (en) Human immunodeficiency virus (hiv) env-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals
Fast et al. Human trials of experimental AIDS vaccines
CN101969996A (zh) 多价疫苗
Natuk et al. Adenovirus-human immunodeficiency virus (HIV) envelope recombinant vaccines elicit high-titered HIV-neutralizing antibodies in the dog model.
EP1601328A2 (en) Polyvalent immunogen
CA2077651C (en) Peptides stimulating cytotoxic t cells immune to hiv rt
Verrier et al. A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates
Clerici et al. Immunization with subunit human immunodeficiency virus vaccine generates stronger T helper cell immunity than natural infection
Kovacs et al. Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160.
HK141594A (en) Peptide fragments of HIV and their use in vaccines and diagnosis
RU2002126396A (ru) Иммуногенная библиотека химерных пептидов, мимикрирующая генетическое многообразие гипервариабельного района v3 белка оболочки gp120 вируса иммунодефицита человека
Earl et al. Isolate-and group-specific immune responses to the envelope protein of human immunodeficiency virus induced by a live recombinant vaccinia virus in macaques
WO1998041536A9 (en) Glycosylation deficient siv and hiv envelope glycoproteins
Böttiger et al. Cross-neutralizing antibodies against HIV-1 (HTLV-IIIB and HTLV-IIIRF) and HIV-2 (SBL-6669 and a new isolate SBL-K135)
DeVICO et al. Purification and partial characterization of human immunodeficiency virus type 2 reverse transcriptase
OA10271A (en) Multiple branch peptide constructions for use against hiv
DE69217614D1 (de) Hybride, lösliche und nicht gespaltene gp160-variante
EP1625144A2 (en) Polyvalent immunogen
Clutton et al. Optimizing parallel induction of HIV type 1-specific antibody and T-cell responses by multicomponent subunit vaccines
Pyle et al. Purification and characterization of the external envelope glycoprotein from two human immunodeficiency virus type 1 variants, HTLV-IIIB and HTLV-IIIRF
Nardelli et al. Design of a complete synthetic peptide-based AIDS vaccine with a built-in adjuvant
Okuda et al. Strong immunogenicity of a multicomponent peptide vaccine developed with the branched lysine oligopeptide method for human immunodeficiency virus infection